Follistim(R) introduced in Japan in a further indication for the treatment of infertility
(sz) Follistim(R), the first recombinant FSH approved in Japan for use in IVF and ICSI, is now also available in Japan for the induction of ovulation in infertile women.
Follistim(R), the first recombinant FSH approved in Japan for use in IVF and ICSI, is now also available in Japan for the induction of ovulation in infertile women. Follistim’s availability in this new indication means that women and their doctors in Japan now have at their disposal a modern fertility treatment in a ready-to-use solution. It is applicable in a full range of fertility treatments associated with assisted reproductive technologies (ART).
Follistim (also branded as Puregon(R)) was approved by the Japanese health authorities for use in ART in August 2005, and at that time, it was the first fertility drug manufactured by recombinant DNA technology to become available on the Japanese market. This breakthrough represented a long-awaited generation change in the treatment of infertility in Japan. Such a shift has also been reflected in the withdrawal of some older types of fertility hormone manufactured from the urine of menopausal women. Follistim is the only recombinant fertility hormone to be specifically approved in Japan for both ovulation induction and controlled ovarian stimulation associated with IVF/ICSI. more…
From: »PipelineReview.com«